Delcath announces an agreement with Instituto Oncológico Baselga to launch Chemosat in Spain
Barcelona, April 2012.- Delcath Systems, Inc. (NASDAQ: DCTH) announced the implementation of an agreement for the initial launch and training for the supply system Delcath Hepatic CHEMOSAT ® with the Instituto Oncológico Baselga (ICB), of the Chiron group, private hospital located in Barcelona. The ICB CHEMOSAT program will be led by Javier Cortés, MD, consultant principal and head of programmes for breast cancer and melanoma. Dr. Cortes is also Deputy Director of the program of breast cancer and melanoma in Hospital Universitario Vall program Chief d ’ Hebron in Barcelona.
Under the terms of the agreement, the company will provide the ICB logistics and necessary clinical training support for the implementation of the therapy of quimiosaturación using the CHEMOSAT system. He is expected that the training will take place in may, and to the complete this Centre will become the first Spain to offer the treatment of quimiosaturación of Delcath.
In relation to the announcement, Dr. Cortes commented that Instituto Oncológico Baselga is committed to offer pioneering treatments to cancer in Spain patients. The data we’ve seen suggest that the Delcath system CHEMOSAT could be a potentially powerful solution in the treatment of liver cancer. We are delighted to be the first institution in Spain begins to explore the potential of this system in patients with liver tumors derived from different types of cancer. ”
this agreement with ICB represents one of our early progress in Spain, which is one of our markets key objective, ” said Eamonn p. Hobbs, President and CEO of Delcath Systems. The ICB is also our fifth Center in our fourth European market, and is the continuation of the centres we have established in France, Germany and Italy. We are satisfied with the pace of the launch of CHEMOSAT in the U.S., and we hope to announce more new agreements in the coming months. ”
Chiron Group about
La Fundación Chiron is the result of the inspiration of Dr. D. Publius cord, who founded the Chiron group hospital in memory of her son. Its objective was to ensure that both the specialized and basic medicine were available for people with fewer resources. Founded in 1992, the Chiron hospital group consists today of seven hospitals in all Spain. thanks to the efforts coordinated in these centres, Quirón clinics are at the forefront of modern medicine.
About Delcath Systems
Delcath Systems, Inc. is a company specializing in the development of medical and pharmaceutical devices principally designed for the Oncology sector. The Delcath systems for quimiosaturación are designed to administer high doses of chemotherapy and other therapeutic agents to diseased organs or parts of the body, while controlling the systemic exposure of these agents. The initial aim of the company is the treatment of the primary types of liver cancer and metastatic. In 2010, Delcath concluded a study of metastatic melanoma in phase 3 and has recently completed the second phase of a trial with multiple treatment groups for other types of liver cancer. The company managed authorization to dispose of the CE marking for the CHEMOSAT liver supply system in April 2011. The company has not yet received the FDA approval for commercial sale of its system in United States.
